Trial Profile
A safety and feasibility trial of an expanded access use of nimotuzumab in children with tumors of central nervous system
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 02 Dec 2015
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Glioma
- Focus Adverse reactions; Expanded access
- 02 Dec 2015 New trial record